Chinese Medicines as an Adjuvant Therapy for Unresectable Hepatocellular Carcinoma during Transarterial Chemoembolization: A Meta-Analysis of Randomized Controlled Trials

<table>Results of Forest plots of comparison of CMs plus TACE alone versus TACE on KPS increased &gt;10 points for HCC patients at middle and late stages. M-H: Mantel-Haenszel estimates; CI: confidence interval; CMs: Chinese medicines; TACE: transcatheter arterial chemoembolization; KPS: karnofsky performance score.</table>

Evidence-Based Complementary and Alternative Medicine

fig5

Figure 5

Figure 5: Chinese Medicines as an Adjuvant Therapy for Unresectable Hepatocellular Carcinoma during Transarterial Chemoembolization: A Meta-Analysis of Randomized Controlled Trials 

Figure 5 | Chinese Medicines as an Adjuvant Therapy for Unresectable Hepatocellular Carcinoma during Transarterial Chemoembolization: A Meta-Analysis of Randomized Controlled Trials 